Open access · OA
via Europe PMC
Blood-Based Inflammatory and Metabolic Biomarkers for Assessing Symptom Burden and Quality of Life in Older Adults with Cancer: A Narrative Review.
Therapeutics and clinical risk management · 2026
Abstract
<h4>Background</h4>To evaluate the clinical utility of blood-based inflammatory and metabolic biomarkers in assessing symptom burden and quality of life among older adults with cancer.<h4>Methods</h4>This review synthesizes current evidence regarding the clinical utility and underlying pathophysiological mechanisms of blood-based biomarkers, focusing particularly on the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and modified Glasgow prognostic score (mGPS).<h4>Results</h4>Elevated inflammatory markers, such as NLR and SII, independently correlate with increased frailty and functional decline. Concurrently, nutritional-metabolic markers, including hypoalbuminemia and a high mGPS, are strongly associated with anorexia and cancer cachexia. These composite indicators effectively capture the synergistic effects of "inflammaging(definition)", neuroinflammation, and tumor-driven metabolic reprogramming.<h4>Conclusion</h4>Objective, cost-effective, and dynamically measurable inflammatory and metabolic biomarkers represent promising adjunctive tools for early symptom screening. The integration of these markers into comprehensive geriatric assessments may enhance risk stratification and symptom management. However, current evidence is constrained by study heterogeneity, retrospective designs, a lack of standardized cutoffs, and insufficient prospective validation in older cancer populations. Therefore, these biomarkers should be regarded as complementary to traditional assessments rather than definitive standalone tools.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.2147/tcrm.s611486
- Canonical
- link ↗
- Fetched
- 2026-07-02 MST
Cite this
APA
L, L., & Y., Z. (2026). Blood-Based Inflammatory and Metabolic Biomarkers for Assessing Symptom Burden and Quality of Life in Older Adults with Cancer: A Narrative Review. <em>Therapeutics and clinical risk management</em>. https://doi.org/10.2147/tcrm.s611486
Vancouver
L L, Y. Z. Blood-Based Inflammatory and Metabolic Biomarkers for Assessing Symptom Burden and Quality of Life in Older Adults with Cancer: A Narrative Review. Therapeutics and clinical risk management. 2026. doi:10.2147/tcrm.s611486.
BibTeX
@article{lu2026BloodB,
title = {Blood-Based Inflammatory and Metabolic Biomarkers for Assessing Symptom Burden and Quality of Life in Older Adults with Cancer: A Narrative Review.},
author = {Lu L and Zhang Y.},
journal = {Therapeutics and clinical risk management},
year = {2026},
doi = {10.2147/tcrm.s611486},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Disease Markers 2017
Open access · CC-BY
DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer
World Journal of Gastrointestinal Oncology 2026
Open access · CC-BY
Modified frailty index and systemic immune-inflammation enable biological risk stratification in geriatric colorectal cancer surgery
World Journal of Gastrointestinal Oncology 2026
Open access · OA
Modified frailty index and systemic immune-inflammation enable biological risk stratification in geriatric colorectal cancer surgery
Copenhagen University Hospital, Rigshospitalet 2023
Open access · US-GOV
The Prevalence and the Prognostic Value of Sarcopenia Among Patients With Haematological Cancer Diseases - A Prospective Observational Cohort Study.
PLoS ONE 2024
Open access · CC-BY
Inflammatory biomarkers and perinatal depression: A systematic review
Frontiers in Pediatrics 2022
Open access · CC-BY